Fresh analysis indicates that people who come off popular weight-loss injections like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Findings released in a leading medical journal shows that while obese individuals can lose a large proportion of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People using these drugs need to be aware of the risk of quick rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting weight in about 18 months.
Comparing Approaches
The study, which reviewed 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.
Scientists note that people who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Experts suggest the way of the drugs accounts for the heightened weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating far more likely."
An Ongoing Issue?
Medical guidelines advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, given the high risk of weight regain, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the chronic character of excess weight," similar to managing diseases like hypertension.
User Experiences
Users who have come off the medication describe a powerful resurgence of appetite.
"I experienced something activating and I was suddenly ravenous," described one woman.
The struggle is compounded if patients have not established lasting lifestyle or habit changes during therapy.
Growing Adoption
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, experts emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and long-term success likely depends on integrated lifestyle support.